Professor, Medicine, University of California San Diego School of Medicine
Oncology
Dr. Stephen B. Howell, MD
|
|
Give Review
Stephen Howell practices Oncology. He went to medical school at Harvard Medical School. Harvard Medical School is a top medical university. Harvard Medical School has a rank of 1 in research and a 12 in primary care He over the years received 1 awards: "Elected Member". Stephen B. Howell, MD has written publications. He has 102 publications published with PubMed. The lastest paper is: 'Role of the glycosyl-phosphatidylinositol anchor in the intracellular transport of a transmembrane protein in Madin-Darby canine kidney cells.' He is registered with Medicare.
Publications
- Platinum Antitumor Complexes: 50 Years Since Barnett Rosenberg's Discovery.
- Integrin αV control of Cu homeostasis and cisplatin sensitivity.
- Reactive oxygen species promote ovarian Cancer progression via the HIF-1α/LOX/E-cadherin pathway.
- Molecular modulation of the copper and cisplatin transport function of CTR1 and its interaction with IRS-4.
- Antiparasitic efficacy of a novel plant-based functional food using an Ascaris suum model in pigs.
- Copper transporter 2 regulates intracellular copper and sensitivity to cisplatin.
- Dynamics of soft nanomaterials captured by transmission electron microscopy in liquid water.
- Characterization of a monoclonal antibody capable of reliably quantifying expression of Human Copper Transporter 1 (hCTR1).
- In vivo time-gated fluorescence imaging with biodegradable luminescent porous silicon nanoparticles.
- The role of metal binding and phosphorylation domains in the regulation of cisplatin-induced trafficking of ATP7B.
- Claudin-3 and Claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1.
- Copper influx transporter 1 is required for FGF, PDGF and EGF-induced MAPK signaling.
- An all-atom model of the structure of human copper transporter 1.
- Sec61β Controls Sensitivity to Platinum-Containing Chemotherapeutic Agents through Modulation of the Copper-Transporting ATPase ATP7A.
- Aggregation properties of a polymeric antiCancer therapeutic: a coarse-grained modeling study.
- Effects of solution concentration on the conformation of a polymeric antiCancer therapeutic: a coarse-grained modeling study.
- A6 peptide Activates CD44 Adhesive Activity, Induces FAK and MEK Phosphorylation and Inhibits the Migration and Metastasis of CD44-Expressing Cells.
- Cisplatin-Loaded Porous Si Microparticles Capped by Electroless Deposition of Platinum.
- Porous Silicon Nanoparticle Photosensitizers for Singlet Oxygen and Their Phototoxicity against Cancer Cells.
- Coarse-grained modeling study of nonpeptide RGD ligand density and PEG molecular weight on the conformation of poly(γ-glutamyl-glutamate) paclitaxel conjug...
- Targeting granzyme B to tumor cells using a yoked human chorionic gonadotropin.
- Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo.
- Characterization of a clinical polymer-drug conjugate using multiscale modeling.
- The role of the methionines and histidines in the transmembrane domain of mammalian copper transporter 1 in the cellular accumulation of cisplatin.
- Copper transporters and the cellular pharmacology of the platinum-containing Cancer drugs.
- Regulation of copper transporter 2 expression by copper and cisplatin in human ovarian carcinoma cells.
- Intra-arterial chemotherapy for head and neck Cancer: is there a verdict?
- CD44-targeted microparticles for delivery of cisplatin to peritoneal metastases.
- Regulation of Cisplatin cytotoxicity by cu influx transporters.
- Tumor platinum concentration following intraperitoneal administration of cisplatin versus carboplatin in an ovarian Cancer model.
- Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin.
- Recombinant CPE fused to tumor necrosis factor targets human ovarian Cancer cells expressing the claudin-3 and claudin-4 receptors.
- Effects of the loss of Atox1 on the cellular pharmacology of cisplatin.
- The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs.
- Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1.
- Dysregulation of purine nucleotide biosynthesis pathways modulates cisplatin cytotoxicity in Saccharomyces cerevisiae.
- Transport of cisplatin by the copper efflux transporter ATP7B.
- Acidic hydrolysis of N-Ethoxybenzylimidazoles (NEBIs): potential applications as pH-sensitive linkers for drug delivery.
- The internalization and degradation of human copper transporter 1 following cisplatin exposure.
- Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin.
- Expression of the human copper influx transporter 1 in normal and malignant human tissues.
- Human REV1 modulates the cytotoxicity and mutagenicity of cisplatin in human ovarian carcinoma cells.
- DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance.
- Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system.
- DNA polymerase zeta accounts for the reduced cytotoxicity and enhanced mutagenicity of cisplatin in human colon carcinoma cells that have lost DNA mismatch repair.
- Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells.
- Suppression of hREV1 expression reduces the rate at which human ovarian carcinoma cells acquire resistance to cisplatin.
- Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian Cancers.
- Intracellular localization and trafficking of fluorescein-labeled cisplatin in human ovarian carcinoma cells.
- DNA polymerase zeta regulates cisplatin cytotoxicity, mutagenicity, and the rate of development of cisplatin resistance.
- The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells.
- The role of copper transporters in the development of resistance to Pt drugs.
- Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells.
- Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian Cancer cells.
- Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B.
- Confocal microscopic analysis of the interaction between cisplatin and the copper transporter ATP7B in human ovarian carcinoma cells.
- A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors.
- Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian Cancer patients.
- The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells.
- Diazonamide A and a synthetic structural analog: disruptive effects on mitosis and cellular microtubules and analysis of their interactions with tubulin.
- Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper.
- Identification of transdominant-negative genetic suppressor elements derived from hMSH2 that mediate resistance to 6-thioguanine.
- The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae.
- Intraperitoneal therapy for stage III ovarian Cancer: a therapy whose time has come!
- Cisplatin induces resistance by triggering differentiation of testicular embryonal carcinoma cells.
- Tumor infiltrating B-cells are increased in prostate Cancer tissue.
- Regulation of the Epithelial-Mesenchymal Transition by Claudin-3 and Claudin-4.
- Expression of an enzymically active glycosylphosphatidylinositol-anchored form of neutral endopeptidase (EC 3.4.24.11) in Cos-1 cells.
- Membrane peptidases on human osteoblast-like cells in culture: hydrolysis of calcitonin and hormonal regulation of endopeptidase-24.11.
- 14-3-3 is phosphorylated by casein kinase I on residue 233. Phosphorylation at this site in vivo regulates Raf/14-3-3 interaction.
- A monoclonal antibody to bovine brain inositol monophosphatase. Immunoaffinity purification of the brain and kidney enzymes and evidence for their structural identity.
- NF-kappaB1 p105 negatively regulates TPL-2 MEK kinase activity.
- Role of the glycosyl-phosphatidylinositol anchor in the intracellular transport of a transmembrane protein in Madin-Darby canine kidney cells.
- Modulation of cytarabine metabolism in the human promyelocytic leukemia cell line HL-60 by polyhydroxy-substituted benzohydroxamic acids.
- Direct targeting of neutral endopeptidase (EC 3.4.24.11) to the apical cell surface of transfected LLC-PK1 cells and unpolarized secretion of its soluble form.
- The regulation of endopeptidase-24.11 expression on human osteoblast-like cells in culture.
- Pilot study of intra-arterial floxuridine, mitomycin and doxorubicin in combination with degradable starch microspheres to treat primary and metastatic tumors of the l...
- The role of specific isoforms of 14-3-3 protein in regulating protein kinase activity in the brain.
- Structure and sites of phosphorylation of 14-3-3 protein: role in coordinating signal transduction pathways.
- Identification and characterisation of a homologue of p64 in rat tissues.
- Mechanism of inhibition of protein kinase C by 14-3-3 isoforms. 14-3-3 isoforms do not have phospholipase A2 activity.
- Role of metallothionein in carcinogenesis.
- Changes in glomerular filtration rate associated with high-dose methotrexate therapy in adults.
- Gene therapy for thioguanine-resistant human leukemia.
- Peritoneal access for intracavitary chemotherapy.
- Regulation of de novo purine synthesis in human bone marrow mononuclear cells by hypoxanthine.
- Pharmacokinetics of intra-arterial mitomycin C with or without degradable starch microspheres (DSM) in the treatment of non-resectable liver Cancer.
- Pharmacologic studies of intra-hepatic artery chemotherapy with degradable starch microspheres.
- Intraperitoneal chemotherapy: the use of concurrent systemic neutralizing agents.
- Thymidine as a chemotherapeutic agent: pharmacologic, cytokinetic, and biochemical studies in a patient with T-cell acute lymphocytic leukemia.
- Changes in gene expression in macrophages infected with Mycobacterium tuberculosis: a combined transcriptomic and proteomic approach.
- Casein kinase I associates with members of the centaurin-alpha family of phosphatidylinositol 3,4,5-trisphosphate-binding proteins.
- ABIN-2 forms a ternary complex with TPL-2 and NF-kappa B1 p105 and is essential for TPL-2 protein stability.
- Activity of free and carrier-bound methotrexate against transport-deficient and high dihydrofolate dehydrogenase-containing methotrexate-resistant L1210 cells.
- Effect of glutathione depletion on sulfate activation and sulfate ester formation in rats.
- Cell interactions in adoptive Immune rejection of a syngeneic tumor.
- Cellular immunity in mice with simian virus 40-induced mKSA tumors: comparison of three assays of tumor immunity.
- Modulation of cytarabine uptake and toxicity by dipyridamole.
- Defects in cell-mediated immunity during growth of a syngeneic simian virus-induced tumor.
- Cytokinetic comparison of thymidine and leucovorin rescue of marrow in humans after exposure to high-dose methotrexate.
- Constraints of philanthropy on determining the distribution of biodiversity conservation funding.
Schools
Harvard Medical School
Massachusetts General Hospital
University Calif Hosps
Sidney Farber Cancer Institute
Procedures Preformed
- Plasmapheresis
Conditions Treated
- Anemia
- Immune Thrombocytopenic Purpura (ITP)
- Leukocytosis
- Lung Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Choice Plus POS II
- Power Select HMO
- Blue Card PPO
- CaliforniaCare HMO
- Blue Cross Blue Shield of California PPO
- Select Plus HMO
- Cigna HMO
- First Health (Coventry Health Care) PPO
- Medicare Advantage PFFS
- Medicare MCR
- Kaiser PHCS Network PPO
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
Awards
- Elected Member
Education
-
UCSF -
Massachusetts General Hospital -
Harvard Medical School
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1114942802 |
| Last Name Of The Provider | HOWELL |
| First Name Of The Provider | STEPHEN |
| View All |
Similar Doctors
|
|
Dr. Joel I. Bernstein, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marie P. Shieh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Grace H. Ku, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eric J. Roeland, MD
This Doctor is OpenDoctor Recommended.
|